Latest Breaking News On - Anticancer therapies - Page 1 : comparemela.com

MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors

TNO155 Plus Spartalizumab or Ribociclib Elicits Disease Control, Is Safe in Advanced Solid Tumors

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

Targeted Delivery of IL-12 Shows Preliminary Antitumor Activity in Advanced Solid Tumors

A high proportion of patients with metastatic solid tumors experienced stable disease following treatment with the immunocytokine in the DODEKA trial.

LoRusso named the Amy and Joseph Perella Professor of Medicine

Patricia LoRusso is an internationally recognized expert in drug development and early-phase clinical investigation of novel cancer therapies.

Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates

Phase 1b/2 trial of AsiDNA™ in combination with olaparib in the United States in recurrent ovarian, breast and metastatic castration-resistant prostate cancer continues to enroll. | April 24, 2023